Phase 2, single group assignment trial NCT01068249 (Slomovitz et al., 2015) evaluated the clinical benefit and the safety of the mTOR inhibitor Everolimus (10 mg/day) combined with Letrozole (2.5 mg/day) in 38 patients with recurrent endometrial cancer at 8 weeks of treatment, then every 12 weeks, up to 2 years. This evidence concerns the gene MTOR and endometrial cancer.